Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes

BACKGROUND: Use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as adjunct therapy to insulin in type 1 diabetes (T1D) has been previously studied. In this study, we present data from the first free-living trial combining low-dose SGLT2i with commercial automated insulin delivery (AID) or pred...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Tirado, Jose, Farhy, Leon, Nass, Ralf, Kollar, Laura, Clancy-Oliveri, Mary, Basu, Rita, Kovatchev, Boris, Basu, Ananda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464084/
https://www.ncbi.nlm.nih.gov/pubmed/35255229
http://dx.doi.org/10.1089/dia.2021.0542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464084/
https://www.ncbi.nlm.nih.gov/pubmed/35255229
http://dx.doi.org/10.1089/dia.2021.0542

Ejemplares similares